Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $990K rose 24.1% year over year, behind the +54.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 60.7% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.

Context

  • Stock-based compensation amounted to 15.8% of revenue in FY2025, up 5.1 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +24.1% toward the trailing-twelve-month pace of +54.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$990K-60.7% QoQ
Last fiscal yearDec 2025
$7.03M+39.0% YoY
LTMMar 2026
$7.23M+54.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.1%——
1 year+39.0%——
3-year CAGR+18.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
7.03M USD
Year-over-year change
+39.0%
4-year CAGR
+15.0%

Stock-Based Compensation vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +54.8% is the 5th highest of 8, against a peer median of +98.0%.
  • Stock-based compensation amounts to 14.1% of revenue for FRX.TO, versus a peer median of 1.6%.
FRX.TO Competitors
Stock-Based Compensation for FRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$9.67M USD+143.3%+84.7%—
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$7.23M USD+54.8%+18.6%14.1%
PRN.TOProfound Medical Corp.LTM Mar 2026$5.55M USD+98.0%+9.0%29.6%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$5.06M CAD+220.3%-44.8%1.6%
TSND.TOTerrAscend Corp.LTM Mar 2026$4.38M USD-55.0%-25.6%1.7%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$3.45M CAD-36.6%—1.3%
DR.TOMedical Facilities CorporationLTM Mar 2026$246K USD+228.0%—0.1%
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$0 CAD-100.0%——
Peer median (excluding FRX.TO) —+98.0%-8.3%1.6%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.35M)(23.71M)(16.05M)(436K)(9.74M)
Depreciation & Amortization000800K103K
Deferred Income Tax00000
Stock-Based Compensation4.02M4.22M5.35M5.06M7.03M
Change in Working Capital(932K)1.1M(6.78M)16.94M(12.04M)
Accounts Receivables0(1.55M)(7.27M)(7.87M)(12.44M)
Inventory0(576K)(1.58M)579K(1.28M)
Accounts Payables(794K)1.61M1.39M(537K)1.39M
Other Working Capital(138K)1.61M683K24.77M282K
Other Non-Cash Items307K466K326K4.61M(26.45K)
Operating Cash Flow(14.22M)(18.06M)(17.14M)26.98M(14.67M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment5M19.94M5M(13M)(19.82M)
Common Stock Issued000045.01M
Common Stock Repurchased0(194K)(78K)(176K)0
Dividends Paid00000
Other Financing Activities(22K)797K1.64M(439K)(190.27K)
Financing Cash Flow4.98M20.73M6.64M(13.62M)25.01M
Effect of Forex Changes0000(1.5M)
Net Change in Cash(9.24M)2.67M(10.51M)13.37M8.83M
Free Cash Flow(14.22M)(18.06M)(17.14M)26.98M(14.67M)

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.